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Abstract
The role of genetic polymorphisms in pediatric brain tumor (PBT) etiology is poorly understood. We hypothesized that 
single nucleotide polymorphisms (SNPs) identified in genome-wide association studies (GWAS) on adult glioma would also 
be associated with PBT risk. The study is based on the Cefalo study, a population-based multicenter case–control study. 
Saliva DNA from 245 cases and 489 controls, aged 7–19 years at diagnosis/reference date, was extracted and genotyped for 
29 SNPs reported by GWAS to be significantly associated with risk of adult glioma. Data were analyzed using unconditional 
logistic regression. Stratified analyses were performed for two histological subtypes: astrocytoma alone and the other 
tumor types combined. The results indicated that four SNPs, CDKN2BAS rs4977756 (p = 0.036), rs1412829 (p = 0.037), 
rs2157719 (p = 0.018) and rs1063192 (p = 0.021), were associated with an increased susceptibility to PBTs, whereas the TERT 
rs2736100 was associated with a decreased risk (p = 0.018). Moreover, the stratified analyses showed a decreased risk of 
astrocytoma associated with RTEL1 rs6089953, rs6010620 and rs2297440 (ptrend = 0.022, ptrend = 0.042, ptrend = 0.029, respectively) 
as well as an increased risk of this subtype associated with RTEL1 rs4809324 (ptrend = 0.033). In addition, SNPs rs10464870 and 
rs891835 in CCDC26 were associated with an increased risk of non-astrocytoma tumor subtypes (ptrend = 0.009, ptrend = 0.007, 
respectively). Our findings indicate that SNPs in CDKN2BAS, TERT, RTEL1 and CCDC26 may be associated with the risk of 
PBTs. Therefore, we suggest that pediatric and adult brain tumors might share common genetic risk factors and similar 
etiological pathways.
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Introduction
Brain tumors are the second most common type of pediatric 
cancer and the leading cause of childhood cancer mortality. The 
etiology of pediatric brain tumors (PBTs) is poorly understood 
(1). As in adults (2), the only established risk factors for brain 
tumors in children are exposure to high doses of ionizing radi-
ation and several inherited disorders, and these cause only a 
minority of cases. Therefore, it is likely that brain tumorigenesis 
results from complex interactions between genetic and epige-
netic variations in concert with exposure to environmental fac-
tors (1).
Although large genetic studies on adult brain tumors have 
been conducted (3–7), very few and only small studies of brain 
tumors in children and adolescents have been reported (8–11). In 
the last few years, four genome-wide association studies (GWAS) 
on adult glioma identified seven susceptibility loci at 5p15.33 
(TERT), 8q24.21 (CCDC26), 9p21.3 (CDKN2A-CDKN2B), 20q13.33 
(RTEL1), 11q23.3 (PHLDB1) and 7p11.2 (EGFR) (4–7). However, lim-
ited data are available on the role of genetic polymorphisms in 
the etiology of PBTs, probably because of difficulties in collecting 
a sufficient number of DNA samples. Considering this lack of 
knowledge about genetic risk factors for brain tumors in chil-
dren, it is important to identify germ-line DNA polymorphisms 
that might influence the susceptibility to PBTs.
The aim of this study, based on the largest series of PBT cases 
to date, was to test the hypothesis that the single nucleotide 
polymorphisms (SNPs) identified by GWAS on adult glioma are 
also associated with the risk of brain tumors in children.
Materials and methods
Study population and procedures
This study is based on the Cefalo study, a large, international, population-
based, case–control study of brain tumors in children and adolescents 
conducted in centers in Sweden, Denmark, Norway and Switzerland. All 
centers followed a common protocol for data collection, as described in 
more detail elsewhere (12,13). Eligible cases were children aged 7–19 years 
during the period 1 April 2004 to 31 August 2008, diagnosed with a pri-
mary intracranial brain tumor defined according to the International 
Classification of Childhood Cancer, third edition (ICCC-3) (14), group 
III, restricted to the third edition of the International Classification of 
Diseases for Oncology (ICD-O-3), location C71 and subclassified according 
to the fourth edition of the World Health Organization (WHO) classifica-
tion of tumors of the central nervous system (15). Medulloblastoma cases 
will be the subject of a separate study and therefore have been excluded 
from the present analysis. Two controls per case were randomly selected 
from the general population matched to the case by age, sex and geo-
graphical region. Interviews were conducted with 352 (82%) cases and 646 
(71%) controls. Participants with neurofibromatosis or tuberous sclerosis 
were excluded from the analyses. The study was approved by the national 
data protection boards and ethical committees in all participating coun-
tries, and written informed consent was obtained from all participants 
and/or their parents.
The Oragene self-collection kit (DNA Genotek, Ottawa, ON, Canada) 
was used for saliva collection and DNA extraction, following the manufac-
turer’s recommended protocol. DNA samples are stored at the Karolinska 
Institutet Biobank. The DNA yield was quantitated by using PicoGreen 
(Invitrogen, Carlsbad, CA). Overall, saliva DNA from 245 cases and 489 con-
trols was included in this study.
SNP selection and genotyping
A total of 29 SNPs reported by GWAS to be significantly associated with 
risk of adult glioma were selected for genotyping (4–7). Genotyping was 
performed at the Mutation Analysis core Facility, Clinical Research Centre, 
Huddinge University Hospital, Stockholm, Sweden, with staff blinded 
to sample status, using the Sequenom iPlex Gold platform with matrix-
assisted laser desorption/ionization-time-of-flight (MALDI-TOF) mass 
spectrometry. The average success rate was 97% and the concordance rate 
for duplicate genotyping was 100%.
Statistical analysis
The consistency of allele frequencies with Hardy–Weinberg equilibrium 
was assessed in the controls for all SNPs using the χ2 goodness-of-fit test, 
and p < 0.001 was considered statistically significant. Analyses were per-
formed based on the subset of Cefalo subjects who provided saliva sam-
ple. Unconditional logistic regression was used to estimate the association 
between SNPs and PBT susceptibility based on the Cochran–Armitage 
trend test of additivity (trend) as well as dominant (DOM) and recessive 
(REC) models, with adjustment for the matching variables (age, sex and 
country). The allelic frequencies of the genotyped SNPs were compared 
between cases and controls using the χ2 test. Analyses were also conducted 
stratified by astrocytoma alone and the combination of other tumor types, 
including ependymoma, intracranial embryonal tumors (except medul-
loblastoma), other gliomas, other specified intracranial neoplasms and 
unspecified intracranial neoplasms. Country specific analyses were per-
formed to assess consistency across countries. The Wald test was used to 
evaluate the significance of interactions between SNPs and demographic 
variables and D´, a measure of the linkage disequilibrium (LD) between 
the genotyped SNPs, was calculated. Haploblocks were defined based on 
the default linkage disequilibrium block parameters in Haploview v4.2. 
Haplotype analyses were performed for the haplotype blocks harboring 
the SNPs that were found to be associated with PBTs. Haplotypes with a 
frequency of >1% were considered in the analyses. The effects of specific 
haplotypes were analyzed if the distribution of all the haplotypes was sug-
gestively different between cases and controls (p < 0.05 for all PBTs; p < 0.1 
for subgroup analyses). Selection of SNPs for the analyses was based on 
a priori knowledge from GWAS on adults, and therefore odds ratios (ORs) 
are presented with 95% confidence intervals (CIs). The possibility of false-
positive findings was, however, considered by also providing the reference 
p value for an experiment-wide significance with Bonferroni correction. 
The analyses were performed using PLINK v1.07 (16) and SAS statistical 
software version 9.3 (SAS Institute, Cary, NC).
Results
We successfully genotyped 29 SNPs in 245 cases and 489 con-
trols. The distributions of allele frequencies in the controls were 
in agreement with the Hardy–Weinberg equilibrium. Table  1 
shows demographic characteristics of cases and controls and 
the distributions of diagnostic subtypes. The age and sex dis-
tributions were similar in cases and controls. More than 50% of 
cases were diagnosed with astrocytoma. No significant interac-
tions were detected between SNPs and confounders including 
age, sex and country (Table 2).
As shown in Table 2, TERT rs2736100 A allele was associated 
with a decreased risk of PBTs [ORDOM 0.66 (95% CI 0.46–0.93), 
p = 0.018], whereas the SNPs rs4977756 G allele [ORDOM 1.45 (95% 
CI 1.03–2.06), p = 0.036], rs1412829 G allele [ORDOM 1.45 (95% CI 
1.02–2.05), p = 0.037], rs2157719 C allele [ORDOM 1.53 (95% CI 1.08–
2.19), p = 0.018] and rs1063192 G allele [ORDOM 1.53 (95% CI 1.07–
2.19), p  =  0.021] in CDKN2BAS were associated with increased 
susceptibility to this tumors.
The stratified analyses of two histological subtypes indicated 
that the risk effects of CDKN2BAS rs1063192, rs2157719, rs1412829 
and rs4977756 remained significant in patients with astrocytoma 
Abbreviataions  
CI confidence interval
GWAS genome-wide association studies
OR odds ratio
PBT pediatric brain tumor
SNP single nucleotide polymorphism 
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(ptrend = 0.036, ptrend = 0.034, ptrend = 0.044 and ptrend = 0.023, respec-
tively), whereas the protective effect of TERT rs2736100 was more 
evident in patients with other brain tumor subtypes [ORDOM 0.53 
(95% CI 0.34–0.85), p  =  0.007]. Moreover, the stratified analyses 
showed a decreased risk of astrocytoma associated with the 
polymorphisms RTEL1 rs6089953 A allele, rs6010620 A allele and 
rs2297440 T allele (ptrend  =  0.022, ptrend  =  0.042 and ptrend  =  0.029, 
respectively), as well as an increased risk of this subtype associ-
ated with the C allele of RTEL1 rs4809324 (ptrend = 0.033). In addi-
tion, an increased risk of non-astrocytoma tumor subtypes was 
associated with the SNPs rs10464870 C allele and rs891835 G allele 
in CCDC26 (ptrend = 0.009 and ptrend = 0.007, respectively) (Table 3).
The non-significant findings, possibly resulting from the 
limited statistical power of the study, are shown in the online 
appendix Supplementary Tables 1–3 (available at Carcinogenesis 
Online) and the raw data showing the number of cases and 
controls for each genotype of significant SNPs are reported in 
Supplementary Table 4 (available at Carcinogenesis Online).
Strong linkage disequilibrium (D´ ≥ 0.95) was observed 
between three of the genotyped SNPs in CDKN2BAS (rs1412829, 
rs2157719 and rs1063192) and four SNPs in RTEL1 (rs6089953, 
rs6010620, rs2297440 and rs4809324). For each of the two blocks, 
three haplotypes with frequency of >1% were found. The dis-
tribution of haplotypes was different for PBT patients com-
pared with controls for the CDKN2BAS block (χ2 = 7.0, df = 2 and 
p = 0.030) and showed a tendency to be different for the RTEL1 
block (χ2 = 5.9, df = 2 and p = 0.053). The most common haplo-
type (ATA) of CDKN2BAS SNPs had a significant protective effect 
compared with the other haplotypes combined [OR 0.75 (95% CI 
0.60–0.93), p = 0.009], whereas the second most common haplo-
type (GCG) had a significant risk effect [OR 1.32 (95% CI 1.06–1.64), 
p = 0.012]. The haplotype analyses suggested an increased risk 
of PBTs by increasing the number of risk alleles in CDKN2BAS 
and RTEL1 SNPs. In the astrocytoma subgroup, the same hap-
loblocks and haplotypes with frequencies of >1% were detected. 
However, in this subgroup, the distribution of haplotypes in the 
RTEL1 block was significantly different between patients and 
controls (χ2 = 9.0, df = 2 and p = 0.011), whereas this difference 
was not statistically significant in the CDKN2BAS block (χ2 = 5.7, 
df = 2 and p = 0.059). In the astrocytoma subgroup, a significant 
protective effect was observed for the most common haplotype 
(ATA) of CDKN2BAS SNPs compared with the other haplotypes 
combined [OR 0.73 (95% CI 0.56–0.95), p  =  0.021], whereas the 
second most common haplotype (GCG) showed a significant 
risk effect [OR 1.34 (95% CI 1.02–1.76), p = 0.036]. Moreover, in the 
RTEL1 block, the second most common haplotype (AATT) had 
a significant protective effect compared with the other haplo-
types combined [OR 0.67 (95% CI 0.47–0.95), p = 0.023], whereas 
the third most common haplotype (GGCC) had a significant risk 
effect [OR 1.57 (95% CI 1.06–2.34), p = 0.026] (Table 4).
Overall, we performed 116 testing procedures as described 
above. When the Bonferroni correction is applied, the reference p 
value is 0.0004 for an experiment-wide significance level of 0.05, 
and 0.0009 for a significance level of 0.10; none of the observed 
associations met these limits. The consistency of results across 
countries was investigated and the results of stratified analyses 
are reported in the online appendix Supplementary Tables 5–8 
(available at Carcinogenesis Online). No significant differences 
between countries were observed.
Discussion
The results of this study indicate that several SNPs associated 
with adult glioma risk are also associated with the risk of PBTs. 
Our findings suggest that SNPs rs4977756 G allele, rs1412829 G 
allele, rs2157719 C allele and rs1063192 G allele in CDKN2BAS 
may increase the risk of PBTs, whereas the A  allele of TERT 
rs2736100 polymorphism may confer protection against PBTs. In 
addition, polymorphisms rs6089953 A allele, rs6010620 A allele 
Table 1. Characteristics of cases and controls
Characteristics Cases Controls
No. of participants 245 489
Sex
 Males 136 (56%) 261 (53%)
 Females 109 (44%) 228 (47%)
Age-group (at reference date)
 7–9 years old 48 (20%) 112 (23%)
 10–14 years old 108 (44%) 219 (45%)
 15–19 years old 89 (36%) 158 (32%)
Country
 Sweden 106 (43%) 174 (36%)
 Norway 24 (10%) 62 (13%)
 Denmark 62 (25%) 134 (27%)
 Switzerland 53 (22%) 119(24%)
Type of tumor (International Classification  
of Childhood Cancer-3 group III)a
 Astrocytoma (IIIb) 134 (55%)
  Pilocytic astrocytoma 93
  Supependymal giant cell astrocytoma 5
  Pleomorphic xanthoastrocytoma 4
  Diffuse astrocytoma 13
  Anaplastic astrocytoma 11
  Fibrillary astrocytoma 2
  Glioblastoma 5
  Giant cell glioblastoma 1
 Other gliomas (IIId) 20 (8%)
  Malignant glioma 11
  Oligoastrocytoma 2
  Oligodendroglioma 6
  Anaplastic oligodendroglioma 1
 Ependymoma (IIIa) 19 (8%)
  Subependymoma 2
  Choroid plexus papilloma 4
  Choroid plexus caricinoma 1
  Ependymoma 7
  Papillary ependymoma 1
  Anaplastic ependymoma 4
 Intracranial embryonal tumors (IIIc) 7 (3%)
  CNS primitive neuroectodermal 
tumor
6
  Neuroepithelioma 1
 Other specified intracranial neoplasms 
(IIIe)
49 (20%)
  Germinoma 7
  Yolk sac tumor 1
  Teratoma, mature 1
  Haemangioblastoma 1
  Desmoplastic infantile ganglioglioma 2
   Dysembryoplastic neuroepithelial 
tumor
6
  Ganglioglioma 26
  Anaplastic ganglioglioma 1
  Centrol neurocytoma 3
  Neurilemoma 1
 Unspecified intracranial neoplasm (IIIf) 16 (6%)
aRestricted to ICD-O-3 location C71, subclassified according to World Health 
Organization histological subclassification, 2007; patients with neurofibromato-
sis and tuberous sclerosis were excluded.
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and rs2297440 T allele in RTEL1 were associated with decreased 
susceptibility to astrocytoma, whereas the C allele of RTEL1 
rs4809324 was associated with an increased risk of this sub-
type. Furthermore, an increased risk of non-astrocytoma tumor 
subtypes associated with polymorphisms CCDC26 rs10464870 C 
allele and rs891835 G allele was detected. Our findings suggest 
that genetic risk profiles of PBTs differ by histology.
To our knowledge, this study represents the largest series of 
pediatric brain tumor cases assembled for genetic association 
testing to date. The association between the 29 SNPs investi-
gated in this study and the risk of PBTs has not been examined 
in previous studies (8–11). The SNPs were selected a priori for 
analyses in this study based on findings in GWAS on adult gli-
oma, and our significant findings of associations between SNPs 
in CDKN2BAS, TERT, RTEL1 and CCDC26, and risk of PBTs were 
consistent with findings on adult brain tumors with respect to 
the direction of ORs for the minor alleles (4–7).
CDKN2BAS (ANRIL) encodes antisense non-coding RNA in 
the INK4 locus which is a long non-coding RNA (ncRNA). The 
exact function of CDKN2BAS is unclear, but it is known to be 
involved in regulating the expression of CDKN2A and CDKN2B 
genes that encode cyclin-dependent kinase inhibitors and block 
cell cycle division during the G1/S phase. Therefore, CDKN2BAS 
has a regulatory role in the context of cellular proliferation, and 
its alterations result in abnormal self-renewing capabilities typi-
cal of cancer cells (17,18). Germ-line mutations in CDKN2BAS 
predispose to a wide variety of human cancers (19,20).
Telomerase reverse transcriptase (TERT) is a catalytic subu-
nit of telomerase that maintains telomere by adding telomeric 
repeat sequences onto chromosome ends. Telomerase expres-
sion can prevent telomere erosion in most eukaryotic cells, 
and cancer cells can prevent telomere loss through the abnor-
mal upregulation of telomerase (21). The mutant allele of TERT 
rs2736100, which is an intronic polymorphism, may downregu-
late telomerase expression and consequently decrease the risk 
of brain tumors.
RTEL1 produces regulator of telomere elongation helicase 
1 which is essential for telomere maintenance and genome 
stability by preventing homologous recombination (22). 
Polymorphisms in RTEL1 are correlated with high grade glioma 
in adults (4,5,7,23). In contrast, CCDC26 variations are associated 
with low grade tumors (4,5,23). CCDC26 encodes a retinoic acid–
dependent regulator of cell differentiation and death. CCDC26 
increases apoptosis induced by death stimuli in neuroblastoma 
cells (24) and in glioblastoma cells with downregulation of tel-
omerase activity (25).
The majority of genetic variations found in this study to be 
associated with the risk of PBTs are related to telomerase activ-
ity which has an important role in the initiation and progression 
of gliomas (26). Moreover, it has been shown that telomerase 
expression is related to high grade gliomas and poor survival 
(27,28). Thus, telomerase could be considered as a therapeutic 
target for brain tumors (29,30).
The aim of this study was to provide evidence of the asso-
ciations between SNPs and PBT risk, and not to investigate the 
mechanisms behind such associations; nevertheless the fact 
that we did not consider the effect of environmental risk factors 
represents a limitation of this work. Therefore, additional studies 
are needed to examine potentially relevant gene-environment 
interactions and to explore the mechanisms through which 
these genetic polymorphisms influence cancer susceptibility.
The present study was conducted based on a specific 
hypothesis that may lead to detection of clinically meaningful 
risk and protective factors. Moreover, the selection of SNPs for 
analysis was based on a priori knowledge from GWAS on adults, 
and therefore Bonferroni correction may be overly conservative 
and may make researchers miss important findings (31). To be 
able to evaluate potential false-positive findings, reference p 
values with Bonferroni corrections have been presented and the 
consistency of results across four countries has been reported. 
No significant differences between countries were observed. 
Replication studies are necessary to confirm these results in 
larger sample sizes.
In conclusion, the present findings indicate that SNPs in 
CDKN2BAS are associated with increased susceptibility to PBTs, 
whereas TERT polymorphisms may decrease the risk of these 
tumors. Moreover, polymorphisms in RTEL1 and CCDC26 genes 
are associated with the risk of astrocytoma and non-astrocy-
toma subtypes, respectively. Thus, we suggest that pediatric and 
adult brain tumors might share common genetic risk factors 
and similar etiological pathways.
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